Drug Trial Radar · NCT07568041
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Sep 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Cenna Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- May 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people. Hypothesis: Researchers believe that 8M2D can be administered safely to healthy adults and to people with early Alzheimer's disease, and that it may reduce levels of amyloid beta. Amyloid beta is a protein that builds up in the brains of people with Alzheimer's disease and is thought to contribute to its progression. The study will be conducted in three parts. In the first two parts, healthy volunteers will receive either a single dose or multiple doses of 8M2D so researchers can understand how the drug moves through the body and whether it causes any side effects. In the third part, a small group of people with early Alzheimer's disease will receive multiple doses so researchers can also begin to assess whether the drug has any effect on amyloid beta levels. Doses will be increased gradually and carefully. An independent safety board will review safety information before any dose increase is allowed. The information gathered in this study will be used to identify the appropriate dose of 8M2D and to help design future studies in people with Alzheimer's disease.
Conditions
- Alzheimer's Disease (AD)
Interventions
8M2DDrug
8M2D administered by subcutaneous injection. Evaluated across single ascending doses (Part I) and multiple ascending doses (Part II) in healthy participants, and as multiple doses in participants with early Alzheimer's disease (Part III).
PlaceboDrug
Matching placebo administered by subcutaneous injection in healthy participants across the single ascending dose (Part I) and multiple ascending dose (Part II) parts of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting treatment-emergent adverse eventsTime frame: Baseline to Day 44
- Number of participants reporting treatment-emergent adverse events that require discontinuation of therapy due to intolerable side effectsTime frame: Baseline to Day 14
- Number of participants reporting injection site reactionsTime frame: Baseline to Day 22
- Number of participants demonstrating abnormal laboratory findingsTime frame: Baseline to Day 14
- Number of participants demonstrating abnormal vital signsTime frame: Baseline to Day 22
- Number of participants demonstrating abnormal vital electrocardiogram (ECG) parametersTime frame: Baseline to Day 15
- Number of participants demonstrating adverse changes in physical and/or neurologic examinationsTime frame: Baseline to Day 22
- Number of participants reporting changes in Columbia-Suicide Severity Rating Scale (C-SSRS) from baselineTime frame: Baseline to Day 22
- Maximum observed concentration (Cmax) of 8M2DTime frame: Baseline to Day 14
- Time to maximum observed concentration (tmax) of 8M2DTime frame: Baseline to Day 14
- Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC-last) of 8M2DTime frame: Baseline to Day 14
- Terminal phase half-life (t1/2)Time frame: Baseline to Day 14
- Area under the concentration-time curve from time 0 to infinity (AUC-inf)Time frame: Baseline to Day 14
- Assessment of changes from baseline after 14 days of dosing in plasma and CSF biomarkers of AD [such as Aβ42, Aβ40, p-tau217, and np-tau217Time frame: Baseline to Day 14
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.